All In Biotech

Drug Trial Radar · NCT00992745

A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Oct 12, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Planned (sponsor's estimate)

Start

Oct 2009

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Sponsor type
Industry
First posted
Oct 9, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Diagnostic
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label study comparing the imaging characteristics of 123-I-MIP-1072 and ProstaScint® (111-In-capromab pendetide)in patients with metastatic prostate cancer. Eligible patients will receive a dose of 123-I-MIP-1072 and have imaging studies and safety assessments (physical examination, vital signs, electrocardiogram, clinical laboratory tests) performed during the subsequent 24 hours. Two weeks later, patients will return for additional safety assessments and will receive ProstaScint® if they don't already have a pre-existing ProstaScint scan. Final assessments will be performed two weeks after the ProstaScint® scan unless there is a difference between the 123-I-MIP-1072 and ProstaScint® scans. If this is the case, another dose of 123-I-MIP-1072 will be given 12 weeks later, and imaging studies repeated.

Conditions

  • Prostate Cancer

Interventions

  • 123-I-MIP-1072Drug

    Single 10 mCi intravenous injection

  • 111-In capromab pendetideDrug

    Single 5 mCi intravenous injection

  • 123-I-MIP-1072Drug

    Single 5 mCi intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimate the imaging sensitivity and specificity of 10.0 mCi or 5.0 mCi of 123I MIP 1072 compared to 5 mCi of 111In capromab pendetide in subjects with metastatic prostate cancer by determining the presence and extent of the disease.Time frame: 24 hours post-injection

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • West Coast Radiology Centers

    Laguna Niguel, California

  • Pacific Coast Imaging

    Newport Beach, California

  • University of California - San Francisco

    San Francisco, California

  • University of Maryland

    Baltimore, Maryland

  • New York Presbyterian Hospital - Weill Cornell Medical College

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Vanguard Urologic Research Foundation

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.